Previous Announcement Regarding Appointment Of NED
28 September 2018 16:00 BST
PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NON-EXECUTIVE DIRECTOR
AstraZeneca PLC (the Company) today announced that with the Company's agreement, Joseph G. Peter (Joe Peter) has withdrawn his candidacy as a Non-Executive Director and a member of the Audit Committee. His proposed appointment to these positions was announced by the Company on 6 September 2018 and was to have become effective on 1 October 2018. Mr Peter's decision is for reasons that are not related to the Company.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
| Media Relations | ||||
| Karen Birmingham | UK/Global | +44 203 749 5634 | ||
| Rob Skelding | UK/Global | +44 203 749 5821 | ||
| Matt Kent | UK/Global | +44 203 749 5906 | ||
| Gonzalo Viña | UK/Global | +44 203 749 5916 | ||
| Jacob Lund | Sweden | +46 8 553 260 20 | ||
| Michele Meixell | US | +1 302 885 2677 | ||
| Investor Relations | ||||
| Thomas Kudsk Larsen | +44 203 749 5712 | |||
| Henry Wheeler | Oncology | +44 203 749 5797 | ||
| Christer Gruvris | Cardiovascular; Metabolism | +44 203 749 5711 | ||
| Nick Stone | Respiratory; Renal | +44 203 749 5716 | ||
| Josie Afolabi | Other | +44 203 749 5631 | ||
| Craig Marks | Finance; Fixed Income | +44 7881 615 764 | ||
| Jennifer Kretzmann | Retail Investors | +44 203 749 5824 | ||
| US toll-free | +1 866 381 7277 | |||
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.